Why Madrigal Pharmaceuticals, Inc. (MDGL) stock fell 8.1% on Tuesday, November 3, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) closed at $396.32, down 8.08% on Tuesday, November 3, 2026, on volume of 1,978,542 shares (7.3× its 3-month average); market value about $9.20B.

What happened: primary sources

Events Nexqual found for MDGL on Tuesday, November 3, 2026 or the trading day before (November 2, 2026):

• Nov 3, 2026: Reported Q3 2026 results: EPS $1.83 vs consensus −$1.09 (beat), revenue $431.3M vs consensus $405.1M (beat). Guidance: The addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026. source
• Nov 3, 2026: Citigroup: Target raised, Buy, price target $725 → $760

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on MDGL

MDGL stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Earnings report: MDGL results, November 3, 2026. Other big moves that day: November 3, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 4, 2026 at 09:48 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 4, 2026 at 09:48 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt